Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1-16 years

Vaccine

Volumn 29, Issue 48, 2011, Pages 8855-8862

  Abarca, Katia ^a   Ibáñez, Isabel ^a   de la Fuente, Pablo ^b   Cerda, Leonardo ^b   Bergeret, Jorge ^b   Frösner, Gert ^c   Ibarra, Humberto ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Hepatitis A; Paediatric; Vaccination; Virosomes

Indexed keywords

HEPATITIS A VACCINE; VIROSOME VACCINE;

ADENOVIRUS INFECTION; ADOLESCENT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CHILD; CHILE; CLINICAL ASSESSMENT; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH PROGRAM; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOMYELITIS; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; VACCINATION;

ADOLESCENT; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; CHILE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MALE; VACCINES, VIROSOME;

EID: 82455162532     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.095     Document Type: Article

References (21)

1. Hepatitis A vaccines - WHO position paper. Wkly Epidemiol Rec 2000;75:38-44.
2. Jacobsen K., Koopman J. The effects of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns. Int J Epidemiol 2005, 34:600-609.
3. Hepatitis A vaccine recommendations. Pediatrics 2007;120:189-199.
4. Fix A., Martin O., Gallicchio L., Vial P., Lagos R. Age-specific prevalence of antibodies to hepatitis A in Santiago, Chile: risk factors and shift in age of infection among children and young adults. Am J Trop Med Hyg 2002, 66:628-632.
5. Lednar W., Lemon S., Kirkpatrick J., Redfield R., Fields M., Kelley P. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 1985, 122:226-233.
6. Valenzuela M., Jacobs R., Arteaga O., Navarrete M., Meyerhoff A., Innis B. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. Vaccine 2005, 23:4110-4119.
7. FitzSimons D., Hendrickx G., Vorsters A., Van Damme P. Hepatitis A and E: update on prevention and epidemiology. Vaccine 2010, 28:583-588.
8. Just M., Berger R., Dreschsler H., Brantschen S., Gluck R. A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks. Vaccine 1992, 10:737-739.
9. ®). Vaccine 2003, 21:4588-4592.
10. ®) in healthy toddlers and children in Chile. Acta Paediatr 2004, 93:412-414.
11. Mayorga Perez O., Herzog C., Zellmeyer M., Loaisiga A., Frosner G., Egger M. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. J Infect Dis 2003, 188:671-677.
12. Dagan R., Amir J., Livni G., Greenberg D., Abu-Abed J., Guy L., et al. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. Pediatr Infect Dis J 2007, 26:787-793.
13. Van der Wielen M., Vertruyen A., Froesner G., Ibanez R., Hunt M., Herzog C., et al. Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years. Pediatr Infect Dis J 2007, 26:705-710.
14. Havrix®. Package insert. GlaxoSmithKline Biologicals Rixensart, Belgium; 2009.
15. Staes C., Schlenker T., Risk I., Cannon K., Harris H., Pavia A., et al. Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. Pediatrics 2000, 106:E54.
16. Prevention of hepatitis A through active or passive immunisation: recommendations of the advisory committee in immunization practices (ACIP). MMWR Recomm Rep 2006, 55(RR-7):1-30. Centers for Disease Control and Prevention.
17. Dagan R., Leventhal A., Anis E., Slater P., Ashur Y., Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005, 294:202-210.
18. Bovier P., Farinelli T., Loutan L. Interchangeability and tolerability of a virosomal and an aluminium-adsorbed hepatitis A vaccine. Vaccine 2005, 23:2424-2429.
19. Clarke P., Adams P., Ibañez R., Herzog C. Rate, intensity, and duration of local reactions to virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers. Trav Med Infect Dis 2006, 4:313-318.
20. van Damme P., Banatvala J., Fay O., Iwarson S., McMahon B., Van Herck K., et al. Hepatitis A booster vaccination: is there a need?. Lancet 2003, 362:1065-1071.
21. Bovier P.A., Bock J., Farinelli Ebengo T., Frösner G., Glaus J., Herzog C. Predicted 30-year protection after vaccination with an inactivated virosome hepatitis A vaccine. J Med Virol 2010, 82:1629-1634.